Investor Presentation in Manchester

RNS Number : 7174H

ValiRx PLC

25 June 2013

 

For release at 07:00 on 25 June 2013

ValiRx Plc

("ValiRx" or the "Company")

INVESTOR PRESENTATION

"Presentation at Proactive Investors One2One Investor Forum

 in Manchester"

ValiRx Plc (AIM: VAL), a life science company with a focus on cancer therapeutics for personalised medicine, is pleased to announce that Dr Satu Vainikka, Chief Executive of ValiRx plc will be making a presentation at the Proactive Investors One2One Investor Forum, The Midland Hotel, Peter Street, Manchester on Wednesday, 26 June 2013.

Further information can be obtained at www.proactiveinvestors.co.uk

The slides will be available from the Company's website, www.valirx.comafter the event.

- ENDS -

For more information, please contact:

ValiRx plc	Tel: [phone]
Dr Satu Vainikka	www.ValiRx.com
Cairn Financial Advisers LLP (Nominated Adviser)	Tel:[phone]
Liam Murray / Avi Robinson
Hybridan LLP (Broker)	Tel: [phone] / 4361
Claire Louise Noyce / William Lynne
Peckwater PR	Tel: [phone]
Tarquin Edwards	[e-mail]

About ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

         ValiFinn is the biomarkers and diagnostic development division

         ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.

 

END

 

 

NRAXZLFLXQFBBBF